Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.069 AUD | -2.82% |
|
-4.17% | +56.82% |
04:20am | Acrux Secures AU$1.5 Million Funding Facility; Shares Fall 3% | MT |
06-17 | Percheron Therapeutics Appoints CFO | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 5 | 100.0 % | 12 | 100.0 % | +133.74% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe and Other Countries
61.1
%
| 1 | 27.8 % | 7 | 61.1 % | +412.74% |
Australia
29.3
%
| 3 | 66.3 % | 3 | 29.3 % | +3.43% |
United States
9.6
%
| 0 | 5.9 % | 1 | 9.6 % | +282.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21-06-20 |
Chief Tech/Sci/R&D Officer | - | 15-02-14 | |
Mark Hyman
PRN | Corporate Officer/Principal | - | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 16-05-31 |
Ross Dobinson
FOU | Founder | 72 | 97-12-31 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Timothy Oldham
BRD | Director/Board Member | - | 13-09-30 |
Donald Brumley
BRD | Director/Board Member | - | 21-06-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 289,630,985 | 238,390,258 ( 82.31 %) | 0 | 82.31 % |
Company contact information
![address Acrux Limited(ACR)](https://cdn.zonebourse.com/static/address/6497341.png)
Sector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+56.82% | 13.71M | |
+20.76% | 43.59B | |
+28.00% | 22.54B | |
+20.25% | 15.73B | |
+18.82% | 14.33B | |
+55.83% | 12.75B | |
-0.05% | 6.79B | |
-12.70% | 6.48B | |
-8.87% | 5.73B | |
+15.72% | 5.67B |
- Stock Market
- Equities
- ACR Stock
- Company Acrux Limited